This article has been updated to include a comment from Perlegen's CEO.

NEW YORK (GenomeWeb News) – Perlegen Sciences, the privately held, Mountain View, Calif.-based pharmacogenomics and genotyping services firm, has ceased operations as of Oct. 30, 2009.

The firm's website has little information remaining on it, but lists as its current contact RoseRyan Inc., a Silicon Valley consulting firm, which a person familiar with the situation said is helping Perlegen close its operations.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: caution urged in use of gene drives, and more.

NIH's Sally Rockey examines the tapped and untapped potential of the NIH peer reviewer pool.

PLOS Biology has asked researchers how they envision the future of genetics and genomics.

Representative Lamar Smith brings back a provision to require the National Science Foundation to certify that each study it funds is "in the national interest."